At present, GenSci has more than 16 projects in the preclinical stage, and 8 projects are undergoing clinical stage. Therapeutic fields include growth and development, assisted reproduction, tumor, immune, antiviral and metabolic diseases, etc.

Our focus is centered on the internationally validated targets of new drug research and development, such as immune checkpoints, interleukin, and some undisclosed novel targets. Our therapeutic modalities include humanized monoclonal antibodies, fully human monoclonal antibodies, Fc fusion proteins, complex glycoproteins, bifunctional antibodies, and Trap, etc.

Some of our projects are biosimilar drugs that have definite curative effect aboard, but are not madein China or are very expensive in Chinese market. The objective of these projects is to market, high-quality drugs available forpatients in China at affordable price.

In short, GenSci is dedicated to serving patients wholeheartedly and to providing high-quality products.